Eric Collisson

Dr. Eric Collisson is a Professor in the Human Biology Division at Fred Hutchinson Cancer Center and Professor in the Department of Hematology and Oncology at the University of Washington School of Medicine. He serves as Director of Translational Integration for the Stuart and Molly Sloan Precision Oncology Institute. His clinical practice focuses on gastrointestinal cancers at the Fred Hutchinson Cancer Center South Lake Union Clinic.

Dr. Collisson holds an MD from UCLA's David Geffen School of Medicine and completed his residency at Stanford University followed by a fellowship at UCSF. His educational background includes a BA from UC Berkeley.

His research centers on how tumor genetics and immune microenvironments shape cancer behavior, particularly in pancreatic and lung cancers. The Collisson Lab investigates intra-patient and inter-patient tumor heterogeneity, tumor-microenvironmental interactions, and employs genetically engineered mouse models, cell lines, and clinically derived samples. His work integrates genomic DNA and mRNA analysis to identify therapeutic targets and advance precision oncology.

Analysis of his publication record reveals consistent focus on pancreatic cancer molecular subtypes, tumor heterogeneity mechanisms, and translational applications of genomic findings. His research bridges basic science with clinical implementation, emphasizing how genetic drivers interact with immune environments to influence treatment response.

Dr. Collisson maintains active clinical and research leadership roles, directing translational integration initiatives while applying genomic technologies to personalize cancer treatment. His laboratory fosters collaborative research through engagement with clinicians and industry partners to accelerate discovery translation.

The Collisson Lab operates at Fred Hutch's South Lake Union campus, utilizing advanced techniques including ArchR scRNA integration and PET CT imaging to study tumor evolution. The lab environment emphasizes collaborative science aimed at transforming cancer treatment through innovative research approaches.